It is estimated that the remaining 20–30% of the common CYP21A2 pathogenic variants in CAH cases involve large gene deletions or amplifications of the CYP21A2 gene and the other contiguous genes. This evidence concerns the gene CYP21A2 and congenital adrenal hyperplasia.